Nanowires enable efficient genetic engineering of non-activated naive T cells, providing a technological platform for the generation of gene-modified T cells with maximal therapeutic efficacy.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Finck, A. V. et al. Nat. Med. 28, 678–689 (2022).
Fraietta, J. A. et al. Nat. Med. 24, 563–571 (2018).
Gattinoni, L. et al. Nat. Rev. Cancer 12, 671–684 (2012).
Gattinoni, L. et al. J. Clin. Investig. 115, 1616–1626 (2005).
Yee Mon, K. J. et al. Nat Nanotechnol. https://doi.org/10.1038/s41565-024-01649-7 (2024).
Ella, S. et al. EBioMedicine 67, 2352–3964 (2021).
Ghassemi, S. et al. Nat. Biomed. Eng. 6, 118–128 (2022).
Mo, F. et al. Nature 597, 544–548 (2021).
Sabatino, M. et al. Blood 128, 519–528 (2016).
Themeli, M. et al. Nat. Biotechnol. 31, 928–933 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
L.G. has consulting agreements with Lyell Immunopharma, is on the scientific advisory boards of Poseida Therapeutics and Kiromic, and is a stockholder of Poseida Therapeutics. D.S.-L. declares no competing interests.
Rights and permissions
About this article
Cite this article
Slavkovic-Lukic, D., Gattinoni, L. Nanowires engineer naive T cells for immunotherapy. Nat. Nanotechnol. 19, 1085–1086 (2024). https://doi.org/10.1038/s41565-024-01651-z
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41565-024-01651-z
